CN1012614B - 头孢-3-烯-4-羧酸衍生物的制备方法 - Google Patents
头孢-3-烯-4-羧酸衍生物的制备方法Info
- Publication number
- CN1012614B CN1012614B CN86104805A CN86104805A CN1012614B CN 1012614 B CN1012614 B CN 1012614B CN 86104805 A CN86104805 A CN 86104805A CN 86104805 A CN86104805 A CN 86104805A CN 1012614 B CN1012614 B CN 1012614B
- Authority
- CN
- China
- Prior art keywords
- acid
- isoxazole
- chlorine
- carboxylic acid
- tetrazolium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims description 25
- 239000002253 acid Substances 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000011541 reaction mixture Substances 0.000 claims description 9
- -1 4-tetrazolium-5-yl Chemical group 0.000 claims description 5
- AYDQIZKZTQHYIY-UHFFFAOYSA-N OC(=O)C1(C)CC(C(O)=O)=CC=C1 Chemical compound OC(=O)C1(C)CC(C(O)=O)=CC=C1 AYDQIZKZTQHYIY-UHFFFAOYSA-N 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 abstract description 31
- 244000005700 microbiome Species 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 16
- 238000012360 testing method Methods 0.000 description 14
- 230000037396 body weight Effects 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical class ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 241000191940 Staphylococcus Species 0.000 description 6
- 159000000000 sodium salts Chemical class 0.000 description 6
- NHNUFAASKXPOQA-UHFFFAOYSA-N (3-acetamido-2-hydroxyphenyl)arsonic acid Chemical compound C(C)(=O)NC=1C(=C(C=CC1)[As](O)(=O)O)O NHNUFAASKXPOQA-UHFFFAOYSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 244000063299 Bacillus subtilis Species 0.000 description 3
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- ODFJOVXVLFUVNQ-UHFFFAOYSA-N acetarsol Chemical compound CC(=O)NC1=CC([As](O)(O)=O)=CC=C1O ODFJOVXVLFUVNQ-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 229960002682 cefoxitin Drugs 0.000 description 3
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 3
- 229960001668 cefuroxime Drugs 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 150000003952 β-lactams Chemical class 0.000 description 3
- HSHGZXNAXBPPDL-HZGVNTEJSA-N 7beta-aminocephalosporanic acid Chemical compound S1CC(COC(=O)C)=C(C([O-])=O)N2C(=O)[C@@H]([NH3+])[C@@H]12 HSHGZXNAXBPPDL-HZGVNTEJSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 2
- 229960003012 cefamandole Drugs 0.000 description 2
- 229940047526 cephalexin monohydrate Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- YGZIWEZFFBPCLN-UHFFFAOYSA-N n,3-bis(2-chloroethyl)-4-hydroperoxy-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-amine Chemical compound OOC1CCOP(=O)(NCCCl)N1CCCl YGZIWEZFFBPCLN-UHFFFAOYSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachlorophenol Chemical compound OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
- IKWLIQXIPRUIDU-ZCFIWIBFSA-N (6r)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical class OC(=O)C1=CCS[C@@H]2CC(=O)N12 IKWLIQXIPRUIDU-ZCFIWIBFSA-N 0.000 description 1
- PMZBHPUNQNKBOA-UHFFFAOYSA-N 5-methylbenzene-1,3-dicarboxylic acid Chemical compound CC1=CC(C(O)=O)=CC(C(O)=O)=C1 PMZBHPUNQNKBOA-UHFFFAOYSA-N 0.000 description 1
- NGHVIOIJCVXTGV-UHFFFAOYSA-N 6beta-amino-penicillanic acid Natural products OC(=O)C1C(C)(C)SC2C(N)C(=O)N21 NGHVIOIJCVXTGV-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000000120 Artificial Saliva Substances 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- GZPRTCWDXFXNIT-UHFFFAOYSA-N O1C=NC=C1.C1(=CC=CC=C1)C1=NOC=C1 Chemical class O1C=NC=C1.C1(=CC=CC=C1)C1=NOC=C1 GZPRTCWDXFXNIT-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical group N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229910001392 phosphorus oxide Inorganic materials 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 108010028349 saliva Orthana Proteins 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- VSAISIQCTGDGPU-UHFFFAOYSA-N tetraphosphorus hexaoxide Chemical compound O1P(O2)OP3OP1OP2O3 VSAISIQCTGDGPU-UHFFFAOYSA-N 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/36—Methylene radicals, substituted by sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU2725/85 | 1985-07-16 | ||
HU852725A HU203243B (en) | 1985-07-16 | 1985-07-16 | Process for producing cefalosporin derivative |
Publications (2)
Publication Number | Publication Date |
---|---|
CN86104805A CN86104805A (zh) | 1987-02-18 |
CN1012614B true CN1012614B (zh) | 1991-05-15 |
Family
ID=10960853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN86104805A Expired CN1012614B (zh) | 1985-07-16 | 1986-07-16 | 头孢-3-烯-4-羧酸衍生物的制备方法 |
Country Status (14)
Country | Link |
---|---|
JP (1) | JPS6222787A (fr) |
KR (1) | KR930007263B1 (fr) |
CN (1) | CN1012614B (fr) |
AT (1) | AT389877B (fr) |
BE (1) | BE905113A (fr) |
DE (1) | DE3623900A1 (fr) |
FI (1) | FI83877C (fr) |
FR (1) | FR2591598B1 (fr) |
GB (1) | GB2177696B (fr) |
GR (1) | GR861855B (fr) |
HU (1) | HU203243B (fr) |
IL (1) | IL79410A0 (fr) |
IT (1) | IT1196494B (fr) |
NL (1) | NL8601842A (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2012729C (fr) | 1989-04-07 | 1997-05-20 | Takashi Kuroda | Moulure mate extrudee-etiree, procede de fabrication |
JP2893286B2 (ja) * | 1990-05-17 | 1999-05-17 | グンゼ株式会社 | 熱収縮性発泡複合フィルム及びその製法 |
JP2515295Y2 (ja) * | 1993-06-30 | 1996-10-30 | 株式会社川崎製作所 | 管継手 |
KR100408343B1 (ko) * | 2001-11-01 | 2003-12-06 | 주식회사 이앤티 | 자돈의 항상성(Homeostasis)을 유지시킬 수 있는 사료 및그 제조방법 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2219775A1 (en) * | 1973-03-02 | 1974-09-27 | Gist Brocades Nv | Isoxazolylacetamido penicillanic and cephalosporanic acids - partic. active against Gram-positive bacteria |
JPS539787A (en) * | 1976-07-16 | 1978-01-28 | Yamanouchi Pharmaceut Co Ltd | Novel cephalosporin derivatives and their preparation |
-
1985
- 1985-07-16 HU HU852725A patent/HU203243B/hu unknown
-
1986
- 1986-07-15 IL IL79410A patent/IL79410A0/xx not_active IP Right Cessation
- 1986-07-15 BE BE0/216927A patent/BE905113A/fr not_active IP Right Cessation
- 1986-07-15 IT IT21135/86A patent/IT1196494B/it active
- 1986-07-15 AT AT0192686A patent/AT389877B/de active
- 1986-07-15 NL NL8601842A patent/NL8601842A/nl not_active Application Discontinuation
- 1986-07-15 KR KR1019860005723A patent/KR930007263B1/ko not_active IP Right Cessation
- 1986-07-15 JP JP61166540A patent/JPS6222787A/ja active Pending
- 1986-07-15 FR FR868610264A patent/FR2591598B1/fr not_active Expired - Lifetime
- 1986-07-15 GB GB08617181A patent/GB2177696B/en not_active Expired
- 1986-07-15 DE DE3623900A patent/DE3623900A1/de not_active Ceased
- 1986-07-16 CN CN86104805A patent/CN1012614B/zh not_active Expired
- 1986-07-16 FI FI862965A patent/FI83877C/fi not_active IP Right Cessation
- 1986-07-16 GR GR861855A patent/GR861855B/el unknown
Also Published As
Publication number | Publication date |
---|---|
FI83877B (fi) | 1991-05-31 |
NL8601842A (nl) | 1987-02-16 |
FR2591598B1 (fr) | 1990-01-26 |
KR870001219A (ko) | 1987-03-12 |
HUT48890A (en) | 1989-07-28 |
FI83877C (fi) | 1991-09-10 |
CN86104805A (zh) | 1987-02-18 |
BE905113A (fr) | 1986-11-03 |
GR861855B (en) | 1986-11-18 |
DE3623900A1 (de) | 1987-01-29 |
IT1196494B (it) | 1988-11-16 |
HU203243B (en) | 1991-06-28 |
JPS6222787A (ja) | 1987-01-30 |
AT389877B (de) | 1990-02-12 |
GB2177696B (en) | 1989-01-05 |
KR930007263B1 (ko) | 1993-08-04 |
FI862965A (fi) | 1987-01-17 |
IL79410A0 (en) | 1986-10-31 |
FI862965A0 (fi) | 1986-07-16 |
FR2591598A1 (fr) | 1987-06-19 |
GB2177696A (en) | 1987-01-28 |
IT8621135A0 (it) | 1986-07-15 |
GB8617181D0 (en) | 1986-08-20 |
ATA192686A (de) | 1989-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1189469C (zh) | 作为抗菌剂的3-(杂芳基乙酰氨基)-2-氧化-氮杂环丁烷-1-磺酸衍生物 | |
CN1028528C (zh) | 旋光活性4-羟基-8-(3-低烷氧基-4-苯基亚磺酰基苯基)吡唑并[1,5-α]-1,3,5-三嗪或其盐的制法 | |
CA2044700A1 (fr) | Cephalosporines comportant en position 3 un radical propenyle substitue par un ammonium guaternaire, leur procede de preparation, leur application comme medicaments, les compositions les renfermant et les nouveaux intermediaire obtenus | |
CN1060778C (zh) | 头孢菌素衍生物 | |
CN1012614B (zh) | 头孢-3-烯-4-羧酸衍生物的制备方法 | |
CN88101541A (zh) | 新的苯并嗪衍生物及其制备方法 | |
EP0197294B1 (fr) | Bêta-lactame antibiotiques, leur procédé de préparation et leur application comme médicaments | |
CN1107067C (zh) | 碳代青霉烯化合物、其用途及其中间体化合物 | |
CN1040109C (zh) | 新头孢菌素类抗生素及其制备方法 | |
CN1052864A (zh) | 喹诺酮化合物及其制备方法 | |
CN88103202A (zh) | 取代的乙烯基头孢菌素类化合物及其制备方法和作为药物的应用 | |
CN1039812C (zh) | 新的头孢菌素及其制备方法 | |
CN87107149A (zh) | 7-[(间位取代的)苯基甘氨酸]1-碳代-1-去硫头孢菌素 | |
CN1086706C (zh) | 吡啶并[3,2,1-i,j][3,1]苯并噁嗪衍生物 | |
BE1007544A3 (fr) | Derives de thioalkylthiocarbacephalosporines. | |
OA12909A (en) | Beta-lactamase inhibitor prodrug. | |
CA2072031A1 (fr) | Cephalosporines comportant un noyau 2-thia cepheme, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et les nouveaux intermediaires obtenus | |
CN1036770A (zh) | 头孢菌素衍生物及其制备方法 | |
CN1116301C (zh) | 四环氟喹诺酮羧酸,其制备方法及其为活性成份的药物组合物 | |
CN87101155A (zh) | 以头孢菌素衍生物作为有效成分的哺乳动物用抗菌剂 | |
CN88103539A (zh) | 制备3,4-二氢-2-烷基-3-氧-N-芳基H-2H-[1]苯并噻吩并[3,2-e]-1,2-噻嗪-4-甲酰胺-1,1-二氧化物的方法 | |
CN1687075A (zh) | 3-苯基异噁唑-5-甲酰胺基取代β-内酰胺类衍生物及其用途 | |
CN1194977C (zh) | 四环氟喹诺酮羧酸,其制备方法及其为活性成份的药物组合物 | |
FR2485540A1 (fr) | Nouveaux derives antibiotiques des cephalosporines, leur procede de preparation et les medicaments en contenant | |
CN86106602A (zh) | 新的头孢菌素衍生物,其制法及含有这些衍生物的医药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C13 | Decision | ||
GR02 | Examined patent application | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |